Exagen Inc
NASDAQ:XGN
Exagen Inc
NASDAQ:XGN
Price:
1.42 USD
0.57%
Updated:
Apr 29, 2024
Section:
Relative Value
The Relative Value of one
XGN
stock under the Base Case scenario is
8.85
USD.
Compared to the current market price of 1.42 USD,
Exagen Inc
is
Undervalued by 84%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
XGN
Relative Value
Base Case
8.85
USD
Undervaluation 84%
Valuation Multiples
Multiples Across Competitors
XGN Competitors Multiples
Exagen Inc Competitors
Exagen Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Exagen Inc
NASDAQ:XGN
|
24.2m USD | 0.5 | -1 | -0.3 | -0.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.5 | 24.7 | 16.3 | 18 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.9B USD | 3.1 | 14.6 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.4B USD | 6.2 | -9 | -9.5 | -8.1 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | |
| IE |
|
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
